PT - JOURNAL ARTICLE AU - Rane, Madhura S. AU - Kochhar, Shivani AU - Poehlein, Emily AU - You, William AU - Robertson, McKaylee M. AU - Zimba, Rebecca AU - Westmoreland, Drew A. AU - Romo, Matthew L. AU - Kulkarni, Sarah G. AU - Chang, Mindy AU - Berry, Amanda AU - Parcesepe, Angela M. AU - Maroko, Andrew R. AU - Grov, Christian AU - Nash, Denis AU - , TI - Determinants and trends of COVID-19 vaccine hesitancy and vaccine uptake in a national cohort of U.S. adults: A longitudinal study AID - 10.1101/2021.05.12.21257116 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.12.21257116 4099 - http://medrxiv.org/content/early/2021/09/10/2021.05.12.21257116.short 4100 - http://medrxiv.org/content/early/2021/09/10/2021.05.12.21257116.full AB - We estimated the trends and correlates of vaccine hesitancy, and its association with subsequent vaccine uptake among 5,458 adults in the United States. Participants belonged to the CHASING COVID Cohort, a national longitudinal study. Trends and correlates of vaccine hesitancy were examined longitudinally in eight interview rounds from October 2020 to July 2021. We also estimated the association between willingness to vaccinate and subsequent vaccine uptake through July 2021. Vaccine delay and refusal decreased from 51% and 8% in October 2020 to 8% and 6% in July 2021, respectively. Compared to Non-Hispanic (NH) White participants, NH Black and Hispanic participants had higher adjusted odds ratios (aOR) for both vaccine delay (aOR: 2.0 [95% CI: 1.5, 2.7] for NH Black and 1.3 [95% CI: 1.0, 1.7] for Hispanic) and vaccine refusal (aOR: 2.5 [95% CI: 1.8, 3.6] for NH Black and 1.4 [95% CI: 1.0, 2.0] for Hispanic) in June 2021. COVID-19 vaccine hesitancy was associated with lower odds of subsequent vaccine uptake (aOR: 0.15, 95% CI: 0.13, 0.18 for vaccine-delayers and aOR: 0.02; 95% CI: 0.01, 0.03 for vaccine-refusers compared to vaccine-willing participants), adjusted for sociodemographic factors and COVID-19 history. Vaccination awareness and distribution efforts should focus on vaccine delayers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina Population Center). The NIH played no role in the production of this manuscript nor necessarily endorses the findings.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referenced in the manuscript are available upon request.COVID-19coronavirus disease-19WHOWorld Health OrganizationUSUnited StatesmRNA(messenger ribonucleic acid)NHNon-HispanicC3 studyCommunities, Households, and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort studySAGEStrategic Advisory Group of Experts on ImmunizationFDAFood and Drug AdministrationGAD-7)Generalized Anxiety Disorder-7NPINon-Pharmaceutical InterventionsGEEgeneralized estimating equationsaORadjusted Odds RatiosCIConfidence Intervals